{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:20:07Z","timestamp":1790713207061,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008093","name":"Schulich School of Medicine and Dentistry","doi-asserted-by":"publisher","award":["Clinician Scientist Award"],"award-info":[{"award-number":["Clinician Scientist Award"]}],"id":[{"id":"10.13039\/501100008093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13014-018-0992-3","type":"journal-article","created":{"date-parts":[[2018,3,29]],"date-time":"2018-03-29T21:49:45Z","timestamp":1522360185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma"],"prefix":"10.1186","volume":"13","author":[{"given":"Rohann J. M.","family":"Correa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belal","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Warner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"MacKenzie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen E.","family":"Pautler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn S.","family":"Bauman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George B.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander V.","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,20]]},"reference":[{"key":"992_CR1","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1097\/01.ju.0000110610.61545.ae","volume":"171","author":"RC Flanigan","year":"2004","unstructured":"Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004;171:1071\u20136.","journal-title":"J Urol"},{"key":"992_CR2","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.1200\/JCO.2016.66.7931","volume":"34","author":"N Hanna","year":"2016","unstructured":"Hanna N, Sun M, Meyer CP, et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016;34:3267\u201375.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"992_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.clgc.2016.04.001","volume":"14","author":"F Petrelli","year":"2016","unstructured":"Petrelli F, Coinu A, Vavassori I, et al. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis. Clin Genitourin Cancer. 2016;14:465\u201372.","journal-title":"Clin Genitourin Cancer."},{"key":"992_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.juro.2010.09.012","volume":"185","author":"TK Choueiri","year":"2011","unstructured":"Choueiri TK, Xie W, Kollmannsberger C, et al. The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol. 2011;185:60\u20136.","journal-title":"J Urol"},{"key":"992_CR5","volume-title":"Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME)","author":"A Bex","year":"2017","unstructured":"Bex A. Immediate versus deferred cytoreductive nephrectomy (CN) in patients with synchronous metastatic renal cell carcinoma (mRCC) receiving sunitinib (EORTC 30073 SURTIME). Madrid: ESMO 2017 Congress; 2017."},{"key":"992_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.clgc.2012.03.008","volume":"10","author":"CK Tsao","year":"2012","unstructured":"Tsao CK, Small AC, Moshier EL, et al. Trends in the use of cytoreductive nephrectomy in the United States. Clin Genitourin Cancer. 2012;10:159\u201363.","journal-title":"Clin Genitourin Cancer"},{"key":"992_CR7","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1002\/ijc.28553","volume":"134","author":"SL Conti","year":"2014","unstructured":"Conti SL, Thomas IC, Hagedorn JC, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. International journal of cancer Journal international du cancer. 2014;134:2245\u201352.","journal-title":"International journal of cancer Journal international du cancer"},{"key":"992_CR8","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1245\/s10434-011-1715-2","volume":"18","author":"F Abdollah","year":"2011","unstructured":"Abdollah F, Sun M, Thuret R, et al. Mortality and morbidity after cytoreductive nephrectomy for metastatic renal cell carcinoma: a population-based study. Ann Surg Oncol. 2011;18:2988\u201396.","journal-title":"Ann Surg Oncol"},{"key":"992_CR9","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2519::AID-CNCR26>3.0.CO;2-E","volume":"80","author":"S Ning","year":"1997","unstructured":"Ning S, Trisler K, Wessels BW, Knox SJ. Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer. 1997;80:2519\u201328.","journal-title":"Cancer"},{"key":"992_CR10","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0090-4295(02)02442-1","volume":"61","author":"LE Ponsky","year":"2003","unstructured":"Ponsky LE, Crownover RL, Rosen MJ, et al. Initial evaluation of Cyberknife technology for extracorporeal renal tissue ablation. Urology. 2003;61:498\u2013501.","journal-title":"Urology"},{"key":"992_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.eururo.2006.03.021","volume":"50","author":"L Walsh","year":"2006","unstructured":"Walsh L, Stanfield JL, Cho LC, et al. Efficacy of ablative high-dose-per-fraction radiation for implanted human renal cell cancer in a nude mouse model. Eur Urol. 2006;50:795\u2013800. discussion.","journal-title":"Eur Urol"},{"key":"992_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.3109\/0284186X.2014.939298","volume":"54","author":"G Kothari","year":"2015","unstructured":"Kothari G, Foroudi F, Gill S, Corcoran NM, Siva S. Outcomes of stereotactic radiotherapy for cranial and extracranial metastatic renal cell carcinoma: a systematic review. Acta Oncol. 2015;54:148\u201357.","journal-title":"Acta Oncol"},{"key":"992_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.critrevonc.2017.07.004","volume":"117","author":"F Alongi","year":"2017","unstructured":"Alongi F, Arcangeli S, Triggiani L, et al. Stereotactic ablative radiation therapy in renal cell carcinoma: From oligometastatic to localized disease. Crit Rev Oncol Hematol. 2017;117:48\u201356.","journal-title":"Crit Rev Oncol Hematol"},{"key":"992_CR14","doi-asserted-by":"publisher","first-page":"E737","DOI":"10.1111\/j.1464-410X.2012.11550.x","volume":"110","author":"S Siva","year":"2012","unstructured":"Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma. BJU Int. 2012;110:E737\u201343.","journal-title":"BJU Int"},{"key":"992_CR15","doi-asserted-by":"crossref","unstructured":"Siva S, Kothari G, Muacevic A, et al. Radiotherapy for renal cell carcinoma: renaissance of an overlooked approach. Nature reviews. Urology. 2017;14:549-563.","DOI":"10.1038\/nrurol.2017.87"},{"key":"992_CR16","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.ijrobp.2017.06.355","volume":"99","author":"S Siva","year":"2017","unstructured":"Siva S, Muacevic A, Staehler M, et al. Individual Patient Data Meta-analysis of SBRT Kidney: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK). International Journal of Radiation Oncology*Biology*Physics. 2017;99:S153\u2013S4.","journal-title":"International Journal of Radiation Oncology*Biology*Physics"},{"key":"992_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11934-016-0581-7","volume":"17","author":"BJ Shin","year":"2016","unstructured":"Shin BJ, Chick JF, Stavropoulos SW. Contemporary Status of Percutaneous Ablation for the Small Renal Mass. Curr Urol Rep. 2016;17:23.","journal-title":"Curr Urol Rep"},{"key":"992_CR18","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1055\/s-0033-1363842","volume":"31","author":"AN Kurup","year":"2014","unstructured":"Kurup AN. Percutaneous ablation for small renal masses-complications. Semin Interv Radiol. 2014;31:42\u20139.","journal-title":"Semin Interv Radiol"},{"key":"992_CR19","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.ijrobp.2003.09.012","volume":"58","author":"S Demaria","year":"2004","unstructured":"Demaria S, Ng B, Devitt ML, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys. 2004;58:862\u201370.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"992_CR20","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1158\/2326-6066.CIR-14-0138","volume":"3","author":"SS Park","year":"2015","unstructured":"Park SS, Dong H, Liu X, et al. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer immunology research. 2015;3:610\u20139.","journal-title":"Cancer immunology research."},{"key":"992_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/PPO.0000000000000210","volume":"22","author":"ED Brooks","year":"2016","unstructured":"Brooks ED, Schoenhals JE, Tang C, et al. Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. Cancer J. 2016;22:257\u201366.","journal-title":"Cancer J"},{"key":"992_CR22","doi-asserted-by":"crossref","unstructured":"Correa RJ, Rodrigues GB, Chen H, Warner A, Ahmad B, Louie AV. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations. Am J Clin Oncol. 2016. Epub ahead of print.","DOI":"10.1016\/S0167-8140(16)33536-8"},{"key":"992_CR23","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/fon.16.2","volume":"12","author":"S Siva","year":"2016","unstructured":"Siva S, Ellis RJ, Ponsky L, et al. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol. 2016;12:637\u201345.","journal-title":"Future Oncol"},{"key":"992_CR24","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","volume":"18","author":"RD Timmerman","year":"2008","unstructured":"Timmerman RD. An overview of hypofractionation and introduction to this issue of seminars in radiation oncology. Semin Radiat Oncol. 2008;18:215\u201322.","journal-title":"Semin Radiat Oncol"},{"key":"992_CR25","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","volume":"27","author":"DY Heng","year":"2009","unstructured":"Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27:5794\u20139.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology."},{"key":"992_CR26","doi-asserted-by":"crossref","unstructured":"Patel HD, Pierorazio PM, Johnson MH, et al. Renal Functional Outcomes after Surgery, Ablation, and Active Surveillance of Localized Renal Tumors: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2017;12:1057-1069.","DOI":"10.2215\/CJN.11941116"},{"key":"992_CR27","doi-asserted-by":"crossref","unstructured":"De Wolf K, Rottey S, Vermaelen K, et al. Combined high dose radiation and tyrosine kinase inhibitors in renal cell carcinoma: a phase I trial. ESTRO Annual Meeting. Vienna, Austria. Radiother Oncol. 2017;12:157.","DOI":"10.1186\/s13014-017-0893-x"},{"key":"992_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","volume":"2","author":"S Demaria","year":"2016","unstructured":"Demaria S, Coleman CN, Formenti SC. Radiotherapy: Changing the Game in Immunotherapy. Trends Cancer. 2016;2:286\u201394.","journal-title":"Trends Cancer"},{"key":"992_CR29","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015;373:1803\u201313.","journal-title":"N Engl J Med"},{"key":"992_CR30","doi-asserted-by":"publisher","first-page":"7516","DOI":"10.4049\/jimmunol.174.12.7516","volume":"174","author":"AA Lugade","year":"2005","unstructured":"Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, Lord EM. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005;174:7516\u201323.","journal-title":"J Immunol"},{"key":"992_CR31","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3857\/roj.2015.33.4.265","volume":"33","author":"MS Kim","year":"2015","unstructured":"Kim MS, Kim W, Park IH, et al. Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery. Radiation oncology journal. 2015;33:265\u201375.","journal-title":"Radiation oncology journal"},{"key":"992_CR32","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1080\/02841860600604611","volume":"45","author":"PJ Wersall","year":"2006","unstructured":"Wersall PJ, Blomgren H, Pisa P, Lax I, Kalkner KM, Svedman C. Regression of non-irradiated metastases after extracranial stereotactic radiotherapy in metastatic renal cell carcinoma. Acta Oncol. 2006;45:493\u20137.","journal-title":"Acta Oncol"},{"key":"992_CR33","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2013.09.018","volume":"356","author":"S Siva","year":"2015","unstructured":"Siva S, MacManus MP, Martin RF, Martin OA. Abscopal effects of radiation therapy: a clinical review for the radiobiologist. Cancer Lett. 2015;356:82\u201390.","journal-title":"Cancer Lett"},{"key":"992_CR34","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1158\/2326-6066.CIR-13-0115","volume":"1","author":"EB Golden","year":"2013","unstructured":"Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer immunology research. 2013;1:365\u201372.","journal-title":"Cancer immunology research"},{"key":"992_CR35","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1593\/tlo.12280","volume":"5","author":"SM Hiniker","year":"2012","unstructured":"Hiniker SM, Chen DS, Reddy S, et al. A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol. 2012;5:404\u20137.","journal-title":"Transl Oncol"},{"key":"992_CR36","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJMoa1112824","volume":"366","author":"MA Postow","year":"2012","unstructured":"Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012;366:925\u201331.","journal-title":"N Engl J Med"},{"key":"992_CR37","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.ctrv.2015.03.011","volume":"41","author":"K Reynders","year":"2015","unstructured":"Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503\u201310.","journal-title":"Cancer Treat Rev"},{"key":"992_CR38","doi-asserted-by":"crossref","unstructured":"Singh AK, Winslow TB, Kermany MH, et al. A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. Clin Cancer Res. 2017;23:5055-5065.","DOI":"10.1158\/1078-0432.CCR-16-2946"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-0992-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-018-0992-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-018-0992-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T12:28:21Z","timestamp":1660739301000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-018-0992-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,20]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["992"],"URL":"https:\/\/doi.org\/10.1186\/s13014-018-0992-3","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,20]]},"assertion":[{"value":"6 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for this study was provided by the Western University Human Studies Research Ethics Board (REB# 15680). All study participants provided written consent to participate in this trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All study participants provided written consent which included consent for the publication of trial results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Louie has received speaker\u2019s honoraria from Varian Medical Systems, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"47"}}